Cardiac Biomarker Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Cardiac Biomarkers Market Summary
Introduction and Market Overview
Cardiac biomarkers are measurable substances in blood that indicate heart conditions, such as troponin for myocardial infarction and NT-proBNP for heart failure. The market is driven by the high prevalence of cardiovascular diseases (CVDs), causing 17.9 million deaths annually, and an aging population projected to reach 2.1 billion by 2050. COVID-19 increased demand, with 16.4% of patients showing cardiac complications. High-sensitivity troponin tests and point-of-care (POC) devices like Abbott’s i-STAT enhance diagnostic speed. The global cardiac biomarkers market is estimated at USD 15-25 billion in 2025, with a CAGR of 12%-18% through 2030.

Regional Market Trends
North America: The U.S. leads with advanced diagnostics and high CVD prevalence, while Canada focuses on POC testing.
Europe: Germany, France, and the UK drive growth with digital health integration, emphasizing early diagnosis.
Asia Pacific: China and India see rapid demand due to rising CVD cases, with Japan prioritizing precision diagnostics.
Rest of the World: Brazil expands biomarker testing in public health, and the Middle East invests in cardiac care infrastructure.

Application Analysis
Laboratory Testing: Expected growth of 12.2%-18.2%, driven by high-throughput diagnostics. Trends focus on AI-driven analysis.
Point of Care Testing: Projected growth of 12.5%-18.5%, linked to rapid diagnostics in emergencies. Advances emphasize portable devices.

Type Analysis
Troponin: Expected growth of 12.7%-18.7%, valued for acute myocardial infarction diagnosis. Trends focus on high-sensitivity assays.
CK-MB: Projected growth of 11.8%-17.8%, used for early CVD detection. Advances emphasize specificity improvements.
Myoglobin: Anticipated growth of 11.5%-17.5%, suited for rapid testing. Trends highlight combination assays.
BNP and NT-proBNP: Expected growth of 12.3%-18.3%, critical for heart failure. Trends focus on risk stratification.
Others: Expected growth of 11.0%-17.0%, covering emerging biomarkers. Trends emphasize precision medicine.

Key Market Players
Roche: Offers high-sensitivity troponin assays.
Abbott: Provides POC testing devices.
Siemens Healthcare: Integrates AI for biomarker analysis.
Quidel Corporation: Focuses on rapid diagnostics.
BIOMÉRIEUX: Emphasizes cardiac infection markers.

Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to high R&D costs and regulatory barriers, but innovation lowers entry hurdles.
Threat of Substitutes: Low, as imaging lacks biomarker specificity, though it complements diagnostics.
Bargaining Power of Buyers: Moderate, with hospitals seeking cost-effective tests, but clinical standards limit options.
Bargaining Power of Suppliers: Low, with multiple reagent providers.
Competitive Rivalry: High, with players competing on test sensitivity and speed.

Market Opportunities and Challenges
Opportunities:
Addressing CVDs, causing 17.9 million deaths annually.
Supporting an aging population with high CVD risk.
Leveraging COVID-19-driven demand for cardiac monitoring.
Utilizing high-sensitivity tests for faster diagnostics.
Aligning with WHO’s digital health strategy for standardization.
Enhancing precision medicine with risk stratification.
Challenges:
High costs of advanced assays and POC devices.
Regulatory delays, with FDA approvals taking 1-2 years.
Limited access in low-income regions.
False positives affecting test reliability.
Integration challenges with EHR systems. Show more